ZIVO Bioscience Past Earnings Performance

Past criteria checks 0/6

ZIVO Bioscience has been growing earnings at an average annual rate of 0.8%, while the Personal Products industry saw earnings growing at 9.3% annually. Revenues have been growing at an average rate of 53.7% per year.

Key information

0.8%

Earnings growth rate

33.0%

EPS growth rate

Personal Products Industry Growth20.9%
Revenue growth rate53.7%
Return on equityn/a
Net Margin-17,327.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

ZIVO Bioscience: Building An IP Portfolio For Algal Biomass Derived Ingredients

Nov 25

Revenue & Expenses Breakdown

How ZIVO Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:ZIVO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-14103
30 Jun 240-13103
31 Mar 240-751
31 Dec 230-861
30 Sep 230-962
30 Jun 230-962
31 Mar 230-972
31 Dec 220-962
30 Sep 220-972
30 Jun 220-972
31 Mar 220-972
31 Dec 210-972
30 Sep 210-752
30 Jun 210-963
31 Mar 210-953
31 Dec 200-954
30 Sep 200-1174
30 Jun 200-1063
31 Mar 200-1164
31 Dec 190-1262
30 Sep 190-1042
30 Jun 190-1342
31 Mar 190-1432
31 Dec 180-1533
30 Sep 180-1543
30 Jun 180-1443
31 Mar 180-1243
31 Dec 170-1042
30 Sep 170-732
30 Jun 170-621
31 Mar 170-731
31 Dec 160-631
30 Sep 160-631
30 Jun 160-631
31 Mar 160-621
31 Dec 150-621
30 Sep 150-421
30 Jun 150-622
31 Mar 150-522
31 Dec 140122
30 Sep 140022
30 Jun 140-121
31 Mar 140-521

Quality Earnings: ZIVO is currently unprofitable.

Growing Profit Margin: ZIVO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ZIVO is unprofitable, but has reduced losses over the past 5 years at a rate of 0.8% per year.

Accelerating Growth: Unable to compare ZIVO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZIVO is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (-5.2%).


Return on Equity

High ROE: ZIVO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 04:33
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ZIVO Bioscience, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anthony VendettiMaxim Group